Drug Discovery Today: Disease Models最新文献_第8页

Non-human primates are essential models in the translational research of multiple sclerosis 非人类灵长类动物是多发性硬化症转化研究的重要模型

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2018.01.001

Bert A. ‘t Hart , Che Serguera , Yolanda S. Kap , Bruno Gran

引用次数: 0

Pancreatic islet xenotransplantation 胰岛异种移植

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2017.11.004

Melanie L. Graham , Henk-Jan Schuurman

引用次数: 7

Measles: What we have learned from non-human primate models 麻疹:我们从非人类灵长类动物模型中学到了什么

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2018.01.002

Rik L. de Swart

引用次数: 7

Editorial to “Use of non-human primate disease models” “非人类灵长类动物疾病模型的使用”社论

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2018.03.002

Theo Vermeire , Romina Aron Badin , Jan Langermans , Mark J. Prescott

引用次数: 0

Non-human primate models and in vitro liver stage cultures as alternatives in malaria drug development 非人类灵长类动物模型和体外肝期培养在疟疾药物开发中的替代作用

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2018.03.001

Anne-Marie Zeeman, Clemens H.M. Kocken

引用次数: 2

Overview of 3Rs opportunities in drug discovery and development using non-human primates 利用非人类灵长类动物进行药物发现和开发的3Rs机会概述

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2017.11.005

Helen Prior , Fiona Sewell , Jane Stewart

{"title":"Overview of 3Rs opportunities in drug discovery and development using non-human primates","authors":"Helen Prior , Fiona Sewell , Jane Stewart","doi":"10.1016/j.ddmod.2017.11.005","DOIUrl":"10.1016/j.ddmod.2017.11.005","url":null,"abstract":"<div><p>Non-human primates (NHPs) are included within safety testing programmes for potential new medicines when justified as the relevant species for use. Although the NHP is often the only relevant species for the testing of large molecule biotherapeutics, a proportion of small molecule compounds may also require testing in NHPs, when other non-rodent species are unsuitable. Whilst the toxicology studies continue to be required for regulatory submissions, there are opportunities to both reduce the number of animals and refine procedures used within the studies, by implementation of best practice study designs and processes identified by NC3Rs-industry data sharing projects. With the rapid expansion of biotherapeutics within the industry expected to continue or increase, the number of compounds within company pipelines, and hence the number of NHPs used for testing, are likewise anticipated to grow. A wider acceptance and adoption of established 3Rs approaches should continue to minimise the use of NHPs whilst maximising the potential these new therapies bring to improve human health.</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2017.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73919436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Non-human primate models for disease and human biology: The impact of the Major Histocompatibility Complex 疾病和人类生物学的非人类灵长类动物模型:主要组织相容性复合体的影响

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2017.11.003

Gaby G.M. Doxiadis, Ronald E. Bontrop

{"title":"Non-human primate models for disease and human biology: The impact of the Major Histocompatibility Complex","authors":"Gaby G.M. Doxiadis, Ronald E. Bontrop","doi":"10.1016/j.ddmod.2017.11.003","DOIUrl":"10.1016/j.ddmod.2017.11.003","url":null,"abstract":"<div><p><span>MHC class I and II molecules play an important role in the adaptive immune response. The genes encoding the MHC molecules are highly polymorphic, thus enabling each molecule to bind a unique repertoire of peptides, which are then presented to </span>T cells<span><span><span>, and may induce an immune reaction. MHC class I and II alleles of non-human primates (NHP) have been shown to influence the susceptibility or resistance to various diseases: for example, autoimmune diseases like rheumatoid arthritis and </span>multiple sclerosis. Thus, knowledge of the susceptibility and/or resistance markers is of value for studying these diseases in experimental settings. Furthermore, in AIDS research, HLA class I molecules of human elite controllers have been shown to share a similar peptide binding motif, like the </span>rhesus macaque<span> class I molecules that are linked to elite control. This finding suggests that immunodominant epitopes of MHC molecules associated with SIV control may also be significant in human HIV control. Thus, macaques have been proven to be an excellent model for HIV/SIV research.</span></span></p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2017.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72601921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applying the 3Rs to non-human primate research: Barriers and solutions 将3r应用于非人灵长类动物研究:障碍与解决方案

Drug Discovery Today: Disease Models Pub Date : 2017-03-01 DOI: 10.1016/j.ddmod.2017.11.001

Mark J. Prescott , Jan A. Langermans , Ian Ragan

{"title":"Applying the 3Rs to non-human primate research: Barriers and solutions","authors":"Mark J. Prescott , Jan A. Langermans , Ian Ragan","doi":"10.1016/j.ddmod.2017.11.001","DOIUrl":"10.1016/j.ddmod.2017.11.001","url":null,"abstract":"<div><p>Progress is being made in the development and application of methods to replace, reduce and refine the use of non-human primates (NHPs) in biomedical research and testing of products and devices. However, there remain considerable cultural and practical barriers to widespread uptake of available 3Rs techniques and to further advancement of the 3Rs in NHP research, over and above scientific obstacles. While most of these barriers apply also to the use of other vertebrate species, there is arguably a greater imperative to overcome them in the case of the NHPs, given their high sentience and the degree of societal concern about their use. To do so will require greater awareness among researchers of the availability and scientific benefits of 3Rs approaches; increased funding for the development of new research models and tools, infrastructure and training; more robust scientific and ethical review of research proposals involving NHPs; better retrospective evaluation of the benefits accrued from NHP research; and improved knowledge transfer. Change is not made without inconvenience, but fully applying the 3Rs to research involving NHPs can improve the quality of science, its translation, business efficiency and public support.</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2017.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25525948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development 定量系统药理学和毒理学模型的发展:通过DILIsym发展的经验和教训

Drug Discovery Today: Disease Models Pub Date : 2016-12-01 DOI: 10.1016/j.ddmod.2017.04.001

Brett A. Howell , Scott Q. Siler , Hugh A. Barton , Elizabeth M. Joshi , Antonio Cabal , Gary Eichenbaum , Paul B. Watkins

{"title":"Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development","authors":"Brett A. Howell , Scott Q. Siler , Hugh A. Barton , Elizabeth M. Joshi , Antonio Cabal , Gary Eichenbaum , Paul B. Watkins","doi":"10.1016/j.ddmod.2017.04.001","DOIUrl":"10.1016/j.ddmod.2017.04.001","url":null,"abstract":"<div><p><span>The development of new pharmaceuticals for the treatment of human disease is increasingly challenging. New methods such as quantitative systems pharmacology (QSP) and quantitative systems toxicology (QST) can help address </span>drug development challenges. Despite its promise, QSP/QST is not without its challenges. An investment is required to collect the necessary input data and ensure key components are represented qualitatively and quantitatively well. One strategy for addressing these concerns is conducting model development within consortia. Consortia offer companies the ability to share data, seek feedback from health authorities collectively, guide model development, learn from others, and share platform development costs. This article highlights lessons learned from past experiences associated with The DILI-sim Initiative – a collaborative effort focused on developing DILIsym software for predicting drug-induced liver injury (DILI).</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2017.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85627930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Virtual liver models in pre-surgical planning, intra-surgical navigation and prognosis analysis 虚拟肝脏模型在术前规划、术中导航和预后分析中的应用

Drug Discovery Today: Disease Models Pub Date : 2016-12-01 DOI: 10.1016/j.ddmod.2017.09.003

Harvey Ho , Adam Bartlett , Peter Hunter

{"title":"Virtual liver models in pre-surgical planning, intra-surgical navigation and prognosis analysis","authors":"Harvey Ho , Adam Bartlett , Peter Hunter","doi":"10.1016/j.ddmod.2017.09.003","DOIUrl":"10.1016/j.ddmod.2017.09.003","url":null,"abstract":"<div><p><span><span>Major liver resection (hepatectomy) is required for patients with liver metastasis<span> (e.g., from colorectal cancer) and hepatocellular carcinoma<span> (e.g., from chronic hepatitis B infection). Hepatectomy is based principally on the segmental anatomy of the liver, which has few reliable external landmarks to orientate the surgeon. Anatomical variations are common and significant flow alterations after surgery are thought to be a cause for </span></span></span>liver dysfunction<span>. Live donor liver transplants (LDLT) are becoming more frequent due to the shortage of cadaver liver donors. Success of this operation is critically dependent on detailed intra-hepatic ‘replumbing’ to achieve adequate vascular and bile flows post-operatively. Models of hepatic anatomy are currently being used to aid pre-surgical planning and intra-operative guidance. Moreover, multi-scale, biophysical and physiological models have been developed for the prediction of flow variations and parenchymal </span></span>regrowth after liver transplantations or major resections. The aim of this paper is to provide a brief review of the state-of-the-art models and new trends.</p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2017.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76578525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1